Cytonics Selects CARA Life Sciences Platform for Rapid eTMF System Implementation

LONDON - EntSun -- Cytonics, a biotechnology research and development company specialising in diagnostics and therapeutics for osteoarthritis, has selected Generis, the provider of the AI-enabled CARA Life Sciences Platform, to manage its electronic Trial Master File (eTMF) and enhance operational efficiency and productivity.

Faced with a need for rapid implementation, Cytonics sought a solution that could be deployed quickly without compromising on capabilities or compliance. The CARA Life Sciences Platform provided the ideal fit: a pre-validated, out-of-the-box eTMF solution that met all functional and regulatory requirements.

"We needed a solution that could be up and running quickly, without a lengthy and complex onboarding process," said Joey Bose, President and CEO at Cytonics. "CARA met all of our requirements—user-friendly, compliant, and ready to go in record time."

CARA's eTMF application delivers a fully compliant, audit-ready environment for managing clinical trial documentation, supported by robust metadata management, workflow automation, and seamless integration capabilities. It also includes DIA reference model alignment, automated trial and site setup, and an integrated site portal for streamlined collaboration.

More on EntSun News

• Sequentex Achieves OMNIA Partners Approval, Empowering Public Sector and other Agencies with Streamlined Technology Procurement
• CEO Selected to Present at Wall Street Conference on May 21, 2025 for Suicidal Depression / PTSD: NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP)
• The World's No.1 Superstar™ shares The ROME-ANTICS Bad Tapes
• $10 Million Plan to Acquire Successful Remote Lottery Platform: Expanding Global Footprint into Live Entertainment: Lottery.com (Stock Symbol: LTRY)
• Assent Launches Carbon Border Adjustment Mechanism Solution to Help Manufacturers Meet Regulatory Requirements

"We're proud to support Cytonics in their mission to improve treatment outcomes for patients around the world," said Max Kelleher, CEO at Generis. "The CARA Life Sciences Platform is a perfect match for companies of all sizes, backed by the depth of experience and innovation our team brings to every project."

By adopting CARA, Cytonics gains a scalable platform that supports future growth and expansion. CARA's built-in AI Assistant further boosts productivity by enabling intuitive access to information and insights—empowering teams to "Chat with Data" for faster, more informed decision-making.

About Generis

Generis is a UK-headquartered developer of world-class data, content and business process management for regulated industries globally. 60% of the top 20 life sciences companies rely on Generis' flagship CARA™ Life Sciences Platform, including AbbVie, UCB, Biogen, Reckitt, Bristol Myers Squibb, Bayer, Pfizer, and Merck KGaA. Today Generis serves more than 750,000 users worldwide, across use cases ranging from RIM, Regulatory / R&D and Safety to Clinical, Non-clinical, Quality GxP, CMC, Pharmacovigilance, Medical Information / Medical Affairs applications and more. More here.

More on EntSun News

• Q1 2025 Revenue Soars 92% to $1.13M on Strategic Acquisitions, Organic Growth & Breakthroughs in AI Drones & Quantum Tech: ZenaTech Stock Symbol: ZENA
• Savista Retreat Announces Monthly Yoga, Wellness & Experiential Retreats in Jaipur
• Robert Tsigler Selected by NADC as Top 1% Attorney in the U.S. for 2025
• Hope in the Stars: Christian Hurst on Identity, Loneliness, and the Voyage of Lily Starling
• **Award-Winning Dystopian Book Series Hitting Too Close to Home**

About Cytonics Corporation
Cytonics is a biotechnology company pioneering treatments in regenerative medicine, with a focus on protein-based therapies for degenerative joint conditions. The company's lead product, CYT-108, is a proprietary fusion protein targeting inflammation in osteoarthritis and other musculoskeletal disorders. More here.